{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055264","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.209088+00:00","generated_at":"2026-05-14T23:34:08.981198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer","bullets":["Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.","Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.","R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.","NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.","Preliminary Phase 1b data readout for NXP900 expected in summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055264","json":"https://secwatch.observer/filing/0001104659-26-055264.json","markdown":"https://secwatch.observer/filing/0001104659-26-055264.md","text":"https://secwatch.observer/filing/0001104659-26-055264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/tm2613389d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:34:08.981198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6942a71dddea88a5c108d25db8520f39b99d618d","claim":"Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}